SEC Form 4 · accession 0001797672-26-000006
Schrodinger, Inc. · SDGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Akinsanya
Officer — See Remarks
Period of report
Sep 17, 2026
Accepted (ET)
Sep 21, 2026 · 5:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001490978
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 17, 2026 | M | 31,599 | $4.34 | A | 101,555 | D | |
| Common StockF2 | Sep 17, 2026 | S | 10,000 | $28.00 | D | 91,555 | D | |
| Common StockF2 | Sep 17, 2026 | S | 21,599 | $30.00 | D | 69,956 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $4.34 | Sep 17, 2026 | M | 31,599 | D | — | Nov 29, 2028 | Common Stock | 31,599 | 11,599 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.
- F2Includes 63,545 unvested RSUs.
- F3This option was granted on November 29, 2018 and is fully vested.
Remarks
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships